Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | MITF | O75030 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.38 |
| ▸ | PDE9A | O76083 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4365755 | 0.84 | TLR7 (0.46) | BRD4MEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL4367588 | 0.84 | TLR7 (0.46) | BRD4MEN1KMT2ASMN1; SMN2NPSR1 | |
| SCHEMBL6017306 | 0.76 | KIF11 (0.46) | EGLN1CYP3A4CYP2C19 | |
| SCHEMBL4365067 | 0.76 | CTSS (0.42) | EGLN1BRD4SMN1; SMN2NPC1MITF | |
| SCHEMBL4361558 | 0.75 | KIF11 (0.63) | CYP3A4CYP2C19 | |
| SCHEMBL6017498 | 0.75 | DPP4 (0.40) | BRD4SMN1; SMN2NPC1MITFHTT | |
| SCHEMBL14408874 | 0.75 | KDM4E (0.47) | MEN1KMT2ASMN1; SMN2NPSR1KDM4E | |
| SCHEMBL13956768 | 0.74 | TLR7 (0.46) | MEN1KMT2AHTTKDM4EMAPT | |
| SCHEMBL4367439 | 0.74 | KIF11 (0.70) | CYP3A4CYP2C19 | |
| SCHEMBL4363445 | 0.74 | PDE1C (0.39) | BRD4MEN1KMT2ASMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1682534-A2 | PYRIMIDIN-4-ONE COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2006-07-26 | — | — | EP | disclosed |
| US-20050197327-A1 | Compounds, compositions, and methods | CYTOKINETICS, INCORPORATED | 2005-09-08 | — | — | US | disclosed |
| WO-2005041888-A2 | PYRIMIDIN-4-ONE COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197327-A1 | Compounds, compositions, and methods | ALPP, PCNA, MKI67 | EGLN1 1946/4885BRD4 1727/4885MEN1 1507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.